Ranbaxy Q4 net seen down 10% at Rs 165 cr

ALSO READ News and Notices about Ranbaxy Labs See interviews with Ranbaxy Labs Management See what other Experts & Brokerages are saying about Ranbaxy Labs See previous Results of Ranbaxy Labs Ranbaxy Labs BSE | NSE 13/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy will declare its Q4 results. According to CNBCTV18 estimates, its Q4 net profit is seen down 10% at Rs 165 crore versus Rs 183.3 crore in the corresponding quarter previous year.

Its net sales are seen up 2% at Rs 1811 crore versus Rs 1776.90 crore.
 
RANBAXY POLL
Q4 CY08 YoY
-Net sales up 2% at Rs 1811 Cr vs Rs 1776.90 Cr
- Operating profit at Rs 283.78 Cr vs Rs 266.5 Cr
-OPM at 15.7 % vs 15 %
- Net profit down 10% at Rs 165 Cr vs Rs 183.3Cr
     # CNBC TV 18 Estimates

RANBAXY POLL
Full Year CY04
-Net sales up 12% at Rs 6851.74 Cr vs Rs 6134 Cr
- Operating profit at Rs 984.28 Cr vs Rs 1330.30 Cr
-OPM at  14.37 % vs  21.69 %
- Net profit up 45% at Rs 745.85 Cr vs Rs 515.10 Cr
     #CNBC TV18 Estimates

RANBAXY
Factors to watch for
-Revenues to expand just about 2% due to higher base of Q4CY07 and absence of big exclusivity in US
-Currency appreciation to impact
-Expect improvement in EBIDTA margins due to higher growth in semi-regulated markets ( including Romania)
-Higher Depreciation and interest cost  will  result in PAT de-growth
-Drop in profit is also because of lower forex gains during the quarter as compared to Q4CY07